0000904454-20-000300.txt : 20200320
0000904454-20-000300.hdr.sgml : 20200320
20200320131614
ACCESSION NUMBER: 0000904454-20-000300
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200318
FILED AS OF DATE: 20200320
DATE AS OF CHANGE: 20200320
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kapusta Matthew C
CENTRAL INDEX KEY: 0001536290
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36294
FILM NUMBER: 20731280
MAIL ADDRESS:
STREET 1: 7358 MCVAY ROAD
CITY: GERMANTOWN
STATE: TN
ZIP: 38138
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: uniQure N.V.
CENTRAL INDEX KEY: 0001590560
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: PAASHEUVELWEG 25A
CITY: AMSTERDAM
STATE: P7
ZIP: 1105 BP
BUSINESS PHONE: 1-339-970-7000
MAIL ADDRESS:
STREET 1: PAASHEUVELWEG 25A
CITY: AMSTERDAM
STATE: P7
ZIP: 1105 BP
FORMER COMPANY:
FORMER CONFORMED NAME: uniQure B.V.
DATE OF NAME CHANGE: 20131030
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2020-03-18
0001590560
uniQure N.V.
QURE
0001536290
Kapusta Matthew C
C/O UNIQURE N.V.
PAASHEUVELWEG 25A
AMSTERDAM
P7
11058BP
NETHERLANDS
1
1
0
0
CEO, CFO, Managing Director
Ordinary Shares
2020-03-18
4
M
0
5626
7.53
A
324168
D
Ordinary Shares
2020-03-18
4
S
0
1888
40.57
D
322280
D
Ordinary Shares
2020-03-18
4
S
0
2100
41.45
D
320180
D
Ordinary Shares
2020-03-18
4
S
0
1438
42.40
D
318742
D
Ordinary Shares
2020-03-18
4
S
0
200
43.70
D
318542
D
Stock Option (Right to Buy)
7.53
2020-03-18
4
M
0
5626
0
A
2026-09-29
Ordinary Shares
5626
87035
D
The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.02 to $40.97. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.03 to 42.02. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.06 to $43.02. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.48 to $43.91. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The Stock Option vested 25% on September 29, 2017 (the first anniversary of the date of grant), and vests 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates.
/s/ Christian Klemt, Attorney-in-Fact
2020-03-20